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The histamine H4 receptor (H4R) is expressed primarily on cells involved in inflammation and immune
responses. Recently, it has been reported the functional expression of H4R within neurons of the central
nervous system, but their role has been poorly understood. The present study aimed to elucidate the
physiopathological role of cerebral H4R in animal models by the intracerebroventricular administration
of the H4R agonist VUF 8430 (20e40 mg per mouse). Selectivity of results was confirmed by the pre-
vention of the effects produced by the H4R antagonist JNJ 10191584 (3e9 mg/kg p.o.). Neuronal H4R
activation induced acute thermal antinociception, indicating that neuronal histamine H4R might be
involved in the production of antinociception in the absence of an inflammatory process. An anxiolytic-
like effect of intensity comparable to that exerted by diazepam, used as reference drug, was produced in
the lightedark box test. VUF 8430 reversed the scopolamine-induced amnesia in the passive avoidance
test and showed anorexant activity in food deprived mice. Conversely, the H4R activation did not modify
the immobility time in the tail suspension test. Rotarod performance test was employed to demonstrate
that the effects observed following the administration of VUF 8430 and JNJ 10191584 were not due to
impaired motor function of animals. Furthermore, both compounds did not alter spontaneous mobility
and exploratory activity in the hole board test. These results show the antinociceptive, antiamnesic,
anxiolytic and anorexant effects induced by neuronal H4R agonism, suggesting that H4 modulators may
have broader utility further the control of inflammatory and immune processes.
 2013 Elsevier Ltd. All rights reserved.1. Introduction
Multiple receptors exist for histamine inmammalian tissues and
these have been classified into 4 distinct receptor types (H1R, H2R,
H3R, and H4R), all of which are G-protein coupled receptors
(GPCRs) (Schneider et al., 2002). The four histamine receptor sub-
types are distinct in terms of their pharmacology and molecular
biology and have been implicated in diverse biological effects of the
neurotransmitter histamine (Haas et al., 2008).
The human histamine H4 receptor (hH4 receptor) is the most
recently discovered member of the G protein-coupled receptor
subfamily of histamine receptors (Nakamura et al., 2000; Oda et al.,
2000; Liu et al., 2001). The H4 receptor mediates its effects by
coupling to Gai/o G-proteins and has low homology with other
histamine receptors, sharing only 35% amino acid identity with the
H3R (58% homology in its transmembrane regions) and a muchax: þ39 (0)55 4271280.
otti).
All rights reserved.lower homology to H1R and H2R (Oda et al., 2000; Nakamura et al.,
2000; Liu et al., 2001).
This receptor has a distinct expression profile on immune cells
including mast cells, eosinophils, dendritic cells, and T cells and
has modulatory functions of these cells, such as, activation,
migration, and production of cytokines and chemokines (O’Reilly
et al., 2002; Hofstra et al., 2003). The characterization of the H4
as the immune system histamine receptor directed growing
attention toward its therapeutic exploitation in chronic inflam-
matory disorders, such as allergy, asthma (Dunford et al., 2006),
chronic pruritus (Dunford et al., 2007; Dijkstra et al., 2007; Bäumer
et al., 2008), inflammatory bowel disease (Varga et al., 2005;
Dunford et al., 2007), and autoimmune diseases, such as rheu-
matoid arthritis (Ikawa et al., 2005) and multiple sclerosis (Jadidi-
Niaragh and Mirshafiey, 2010).
Interestingly, the recently reported functional expression of H4
receptors on human and rodent neurons highlights their implica-
tion in neuronal functions. H4R expression has been reported in
peripheral nerves and in the neurons of the submucous plexus
(Nakaya et al., 2004; Breunig et al., 2007). More recently it has been
observed the presence of H4R receptors in numerous areas of the
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amygdala, cortex, striatum and spinal cord (Strakhova et al., 2009;
Connelly et al., 2009). Electrophysiological studies showed that H4R
directly hyperpolarized cortical neurons (Connelly et al., 2009).
More recent studies on the potential roles for H4R in the human
brain from its predicted functional interactions in the human pro-
teome suggested the participation of H4R in circadian cycle mod-
ulation, neuronal firing inhibition and, in cooperation with H3R, in
thyroid function and appetite coordination (Moya-Garcia et al.,
2011).
The elucidation of the neuronal processes modulated by
neuronal H4 receptors might help clarify the physiological and
pathological role of this receptor subtype within the central ner-
vous system. For these reasons, the present study used VUF 8430, a
H4 agonist (Lim et al., 2009), and JNJ 10191584 (also known as VUF
6002), a potent and selective H4 antagonist (Terzioglu et al., 2004),
to explore the cerebral role of the H4R.2. Materials and methods
2.1. Animals
Male Swiss albino mice (20e22 g) from the Morini (San Polo d’Enza, Italy)
breeding farm were used. Ten mice were housed per cage (26  41 cm). The cages
were placed in the experimental room 24 h before the test for acclimatization. The
animals were fed a standard laboratory diet and tap water ad libitum and kept at
23 1 C with a 12 h light/dark cycle, light on at 7 a.m. All experiments were carried
out in accordance with the European Communities Council Directive of 24
November 1986 (86/609/EEC). All efforts were made to minimize animal suffering
and to reduce the number of animals used.2.2. Behavioral testing
Animals were habituated to the experimental room and randomly assigned to
each treatment group. Mice were investigated by observers blinded for treatment of
the animals. Ten animals per group were used.
2.2.1. Tail suspension test
A piece of tape was adhered to the upper middle of the tail of each animal,
creating a flap with the overlap of tape. Mice were suspended from a plastic rod
mounted 50 cm above the surface by fastening the tail to the rodwith adhesive tape.
The duration of the test was 6 min and immobility was measured the last 4 min to
facilitate comparison with the forced swimming test. Immobility was defined as the
absence of any limb or body movements, except those caused by respiration.
2.2.2. Evaluation of food consumption
Mice did not have access to food for 12 h but water was available ad libitum. A
weighed amount of food (standard laboratory pellets) was given and the weight
consumed (evaluated as the difference between the original amount and the food
left in the cage, including spillage), was measured 15, 30, 45 and 60 min after in-
jection, to an accuracy of 0.1 g. An arbitrary cut-off time of 60 min was used.
2.2.3. Rotarod test
The apparatus consisted of a base platform and a rotating rod of 3 cm diameter
with a non-skid surface. The rod was placed at a height of 15 cm from the base. The
rod, 30 cm in length, was divided into 5 equal sections by 6 disks. Thus up to 5 mice
were tested simultaneously on the apparatus, with a rod-rotation speed of 16 r.p.m.
The integrity of motor coordination was assessed on the basis of the number of falls
from the rod in 30 s. Performance time was measured before and 15, 30, 45 and
60 min after i.c.v. administration of saline or VUF 8430 and after p.o. administration
of CMC or JNJ 10191584.
2.2.4. Locomotor activity
The locomotor activity was evaluated by using the hole-board test. The appa-
ratus consisted of a 40 cm square plane with 16 flush mounted cylindrical holes
(3 cm diameter) distributed 4  4 in an equidistant, grid-like manner. Mice were
placed on the center of the board one by one and allowed to move about freely for a
period of 5 min each. Two photobeams, crossing the plane from mid-point to mid-
point of opposite sides, thus dividing the plane into 4 equal quadrants, automati-
cally signaled the movement of the animal (counts in 5 min) on the surface of the
plane (locomotor activity). Miniature photoelectric cells, in each of the 16 holes,
recorded (counts in 5 min) the exploration of the holes (exploratory activity) by the
mice.2.2.5. Passive-avoidance test
The apparatus consisted of a two-compartment acrylic box with a lighted
compartment connected to a darkened one by a guillotine door. As soon as the
mouse entered the dark compartment, it received a punishing electrical shock
(0.5 mA, 1 s). The latency times for entering the dark compartment were measured
in the training test and after 24 h in the retention test. The maximum entry latency
allowed in the training and retention sessions was, respectively, 60 and 180 s.
2.2.6. Hot-plate test
The hot plate test was performed as previously described (Galeotti et al., 2003).
Micewere placed inside a stainless steel container, whichwas set thermostatically at
52.5  0.1 C in a precision water-bath from KWMechanical Workshop, Siena, Italy.
Reaction times(s), weremeasuredwith a stopwatch before and 15, 30, 45 and 60min
after administration of the analgesic drug. The endpoint used was the licking of the
fore or hind paws. Those mice scoring less than 12 and more than 18 s in the pretest
were rejected (30%). An arbitrary cut-off time of 45 s was adopted.
2.2.7. Light dark box
The lightedark box was made of white and black opaque apparatus (length
50 cm, width 20.5 cm, and height 19 cm) consisted of two equal acrylic compart-
ments, one dark and one white, illuminated by a 60-W bulb lamp and separated by a
divider with a 10  3.2 cm opening at floor level. Each mouse was placed in the
middle of the light chamber facing a side away from the door and then released.
Animals’ behaviors were scored for 5 min and included the duration of time spent in
the light chamber, number of full-body transitions between chambers. These be-
haviors have previously been measured as a reflection of anxiety in this apparatus
(Bourin and Hascoët, 2003). After testing, subjects were removed from the lighte
dark box and returned to their home cage in colony room. The apparatus was
cleaned with 70% ethanol after each use and allowed to dry before the next subject
was tested.
This test exploited the conflict between the animal’s tendency to explore a new
environment and its fear of bright light.
2.3. Drug administration
VUF 8430, scopolamine hydrobromide, naloxone hydrochloride, mecamylamine
hydrochloride, atropine sulfate, yohimbine hydrochloride, (Sigma, Milan, Italy)
morphine hydrochloride (SALARS, Milan, Italy), amitriptyline, D-amphetamine (De
Angeli, Rome, Italy), were dissolved in isotonic (NaCl 0.9%) saline solution imme-
diately before use. JNJ 10191584 (Sigma, Milan, Italy) was dispersed in 1% sodium
carboxymethylcellulose (CMC) and administered by gavage 30 min before behav-
ioral testing. Drug concentrations were prepared in such a way that the necessary
dose could be administered in a volume of 10 ml/kg by intraperitoneal (i.p.) or
gavage (p.o.) administration, or in a volume of 5 ml per mouse by intra-
cerebroventricular (i.c.v.) injection.
Animals were used a single time and were randomly assigned to the treatment
groups. To evaluate the role of H4R within the central nervous system, VUF 8430
(20e60 mg per mouse) was administered i.c.v., as previously described (Galeotti
et al., 2003), 15 min before the tests. Naloxone (1 mg/kg), atropine (5 mg/kg),
mecamylamine (2 mg/kg) were administered 15 min before the test, diazepam
(1 mg/kg), amitriptyline (10 mg/kg) 30 min before, yohimbine (2 mg/kg) 60 min
before, intraperitoneally. Scopolamine (3 mg/kg i.p.) was administered immediately
after the training session. Doses and administration schedule were chosen on the
basis of time-course and doseeresponse curves performed in our laboratory.
2.4. Statistical analysis
All experimental results are given as the mean  s.e. mean. One-way and two-
way analysis of variance, followed, respectively, by Tukey and Bonferroni post hoc
test, were used for statistical analysis.
3. Results
3.1. Antinociceptive effect of the H4 receptor agonist VUF 8430
The involvement of histamine H4 receptors in the modulation of
the pain threshold following an acute thermal stimulus was eval-
uated in the mouse hot plate test. The H4 receptor agonist VUF
8430 induced a dose-dependent antinociceptive effect. Two-way
ANOVA for repeated measures yielded a significant main effect
for VUF 8430 treatment (F(3,180) 66.18; P < 0.0001), time (F(4,180)
17.25; P < 0.0001) and interaction (F(12,180) 3.774; p < 0.0001).
Post hoc comparison showed that the dose of 20 mg per mouse i.c.v.
was devoid of any effect, at 30 mg per mouse VUF 8430 significantly
increased the licking latency value at 30 min, and at the dose of
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that peaked at 30min andwas still significant after 60min (Fig. 1a).
This increase of the pain threshold was related to the stimulation of
the H4R since it was selectively prevented by the H4R antagonist
JNJ 10191584 (Fig. 1b). Two-way ANOVA for repeated measures
showed a significant main effect for treatment (F(3,180) 46.00;
P < 0.0001), time (F(4,180) 19.84; P < 0.0001) and interaction
(F(12,180) 3.110; p < 0.0001). The opioid antagonist naloxone, the
muscarinic antagonist atropine, the a2-adrenoceptor antagonist
yohimbine and the nicotinic antagonist mecamylamine did not
modify the VUF 8430-induced antinociceptive effect (Fig. 1c),
further confirming the H4R-mediated mechanism. The selectivity
of JNJ 10191584 was demonstrated by the inefficacy on preventing
morphine (7 mg/kg i.p.) analgesia (Fig. 1d).
3.2. Anxiolytic-like effect following H4 receptor stimulation
Diazepam was used as a reference molecule. It was able to
prolong the time spent in the lighted compartment, thus
evidencing its anxiolytic-like properties and validating our exper-
imental approach. Similarly, the H4R agonist VUF 8430 dose-
dependently prolonged the time spent in the light chamber. At
20 mg it was ineffective, at 30 mg it lightly increased the permanence
in the light without reaching the statistical significance whereas
the dose of 40 mg markedly increased the time spent in the light
compartment producing an anxiolytic effect comparable to that
induced by diazepam (Fig. 2a). In order to confirm that the anxio-
lytic properties of VUF 8430 were related to the stimulation of H4
receptors, we performed experiments in the presence of increasing
concentrations of the H4 antagonist JNJ 10191584. The H4 antago-
nist never modified the time spent in the light when administered
alone, but it was able to completely prevent the VUF 8430-induced
anxiolytic effect when orally administered at the dose of 2 mg/kg
(Fig. 2b).15
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Fig. 1. Antinociceptive effect following H4R activation. (a) The H4R agonist VUF 8430 (20e40
plate test (b) the antinociceptive effect of VUF 8430 was prevented by the H4R antagonist J
yohimbine on VUF 8430-induced antinociception (one-way ANOVA, F(6,69) 3.577). (d) JNJ
**P < 0.01, ***P < 0.001 vs control group; BBP < 0.01, BBBP < 0.001 vs VUF 8430-treatedA second behavioral parameter detected to evaluate the anxio-
lytic efficacy of the H4 receptor agonist was the number of transi-
tions from the two chambers. The reference drug diazepam
markedly increased the transitions in comparison with the control
group. In agreement with data on the time spent on the light,
JNJ10195184 was devoid of any effect when administered alone.
Surprisingly, the H4R agonist, at the dose able to prolong the
permanence in the light compartment, significantly reduced the
number of transfers. This effect was not prevented by pre-treat-
ment with the H4R antagonist (Fig. 2c).
3.3. Antiamnesic activity of a H4 receptor agonist
The administration of scopolamine induced amnesia in the
passive avoidance, as showed by the reduction of the latency to
enter the dark compartment in the retention session. Pre-
treatment with the H4 receptor agonist VUF 8430 (40 mg per
mouse) enhanced the entrance latency to values comparable to the
control group showing a complete prevention of the scopolamine-
induced memory impairment. No ameliorative effect on memory
performancewas detected when VUF 8430 was administered alone
(Fig. 3).
3.4. Anorexant effect by H4R stimulation
The cumulated amount of food eaten by mice which had no
access to food for 12 h before the test is reported in Fig. 3. Mice
showed a constant increase in the amount of food consumed in the
60 min test. Two-way ANOVA for repeated measures yielded a
significant main effect for treatment (F(2,108) 107.6; P < 0.0001),
time (F(3,108) 366.9; P < 0.0001) and interaction (F(6,108) 8.76;
p < 0.0001). Post hoc comparison showed that VUF 8430 (40 mg per
mouse i.c.v.) significantly reduced food consumption 45 and 60min
after administration. No effect was detected at 15 and 30 min.15
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drug (Fig. 4).
3.5. Lack of antidepressant-like activity following H4 receptor
stimulation
VUF 8430, at all doses investigated that resulted effective in the
above-mentioned behavioral paradigms, did not modify the
immobility time in the tail suspension test (TST), showing the lack
of antidepressant-like activity. The administration of amitriptyline,used as reference drug, decreased the immobility time values in the
mouse TST, thus validating our experimental results (Fig. 5).3.6. Effect of H4 receptor modulation on locomotor behavior
The H4 receptor agonist VUF 8430 and the H4 receptor antag-
onist JNJ 10191584 were tested in order to assess their effect on
mouse locomotor behavior. Mice pretreated with the above-
mentioned compounds were evaluated for motor coordination by
use of the rotarod test and for spontaneous mobility and explor-
atory activity by use of the hole board test.
Two-way ANOVA for repeated measures yielded a significant
main effect for treatment (F(3,180) 32.49; P < 0.0001), time
(F(4,180)12.60; P < 0.0001) and interaction (F(12,180) 2.22;
p < 0.0125). Post hoc comparison showed that the lack of any
impairment in the motor coordination after administration of VUF
8430 at the dose of 40 mg per mouse. At the dose of 50 mg there was
a trend to higher values of number of falls without reaching the
statistical significance whereas at the dose of 60 mg VUF 8430
produced a significant impairment in the motor coordination
(Fig. 6A). The H4R antagonist JNJ 10191584 (9 mg/kg p.o.) did not
A6
7
**
**
 
30
s
2
3
4
5 SAL
VUF 40
VUF 50
VUF 60
*
u
m
be
r 
of
 
fa
lls
 i n
pretest 15 30 45 60
0
1
min after administration
n
B
5
6
7
CMClls
 
in
 
30
s
1
2
3
4
JNJ 9
n
u
m
be
r 
of
 
fa
150
200
50
100
***
im
m
ob
ilit
y 
tim
e 
(s)
0
20 4030
SAL VUF 8430 AMI
Fig. 5. Lack of effect of H4R modulation in the mouse tail suspension test. VUF 8430
(20e40 mg per mouse i.c.v.) did not modify the immobility time of animals. Amitrip-
tyline (AMI) was used as antidepressant reference drug. ***P < 0.001 in comparison
with control mice.
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control group (Fig. 6B).
The spontaneous mobility and exploratory activity of mice
treated with VUF 8430 (40 mg per mouse i.c.v.) or JNJ 10191584
(9 mg/kg p.o.) were unmodified in comparison with the control
group (Fig. 6C).C
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higher than dose effective in behavioral tests (50e60 mg per mouse i.c.v.) induced
motor incoordination in the mouse rotarod test. (B) JNJ 10191584 did not alter motor
coordination. (C) The absence of any alteration of spontaneous mobility and explor-
atory activity by the H4R agonist VUF 8430 and the H4R antagonist JNJ 10191584 was
observed in comparison with control (CTRL) mice. *P < 0.05, **P < 0.01 in comparison
with control group.4. Discussion
The central histaminergic system has been implicated in the
regulation of awide range of physiological functions. The role of H1,
H2 and H3 receptor subtypes in the modulation of neuronal pro-
cesses has been widely investigated. Conversely, the role of
neuronal H4 receptors is poorly understood. The present study
investigated the involvement of H4 receptors in the histaminergic
regulation of neuronal functions, such as locomotor activity,
memory, pain perception, feeding behavior, depressive behavior,
anxiety, by using a potent H4 agonist, VUF 8430 (Lim et al., 2009), in
mice. Since H4 receptors have a broader distribution than areas of
the central nervous system, VUF 8430 was administered intra-
cerebroventricularly (i.c.v.) to avoid any interference by peripheral
H4R activation.
VUF 8430 produced a dose-dependent increase of pain
threshold against an acute thermal stimulus. This modulation of
the pain perceptionwas related to an interactionwith histamine H4
receptors since the antinociception was antagonized by JNJ
10191584, a potent and selective H4 receptor antagonist (Terzioglu
et al., 2004), at a concentration devoid of any effect on pain
threshold when administered alone. The involvement of other
neurotransmission systems can be ruled out since the VUF 8430-
induced thermal antinociception was unmodified by the treat-
ment with the opioid antagonist naloxone, the a2-adrenoceptor
antagonist yohimbine, the muscarinic antagonist atropine, the
nicotinic antagonist mecamylamine. Furthermore, the selectivity of
JNJ 10191584 was demonstrated by the lack of any effect of the H4
receptor antagonist on analgesia unrelated to the histaminergic
system. These results, indicating the involvement of neuronal H4
receptors in acute thermal antinociception, are in agreement with
previous studies reporting the decrease in mechanical hyperalgesia
produced by VUF 8430 in a model of neuropathic pain (Smith et al.,
2007). However, in contrast with our findings, it has been observed
that the systemic administration of the H4 antagonists JNJ7777120
and JNJ 10191584 exhibited anti-hyperalgesic activity in different
models of inflammatory pain and anti-allodynic effects in models
of neuropathic pain (Coruzzi et al., 2007; Hsieh et al., 2010). This
discrepancy might be explained considering that this anti-hyperalgesic effect is obtained following systemic administration
of the H4 antagonists and, as stated by the authors, it appears to be
secondary to the anti-inflammatory activity induced by the
antagonism of the H4 receptor on immune system cells. Similarly,
the anti-allodynic effect, which is weaker than the anti-
inflammatory one, origins from the reduction of the inflamma-
tory response at the site of injury in the animal model of neuro-
pathic pain. This hypothesis is further supported by the
observations that the H4 antagonist JNJ7777120 did not produce
any antinociceptive effect on the contralateral non-inflamed paw
(Hsieh et al., 2010). Present results indicate that neuronal histamine
H4 receptor activation might be involved in the production of an
acute thermal antinociception in the absence of an inflammatory
process. H4 receptor modulation might have a broader utility in
pain states than those secondary to inflammation.
Ample evidence has shown that histamine release is a sensitive
indicator of stress and the involvement of the histaminergic system
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suggested. The administration of histamine or L-histidine induces
an anxiogenic-like effect (Kumar et al., 2007) whereas the
destruction of the rat tuberomammillary rostroventral E-2 sub-
region, from which histaminergic neuron fibers arise, can induce
anxiolytic-like effects (Frisch et al., 1998). Furthermore, clinically
effective anxiolytic drugs, such as diazepam and buspirone, have
been found to decrease the turnover rate of brain histamine inmice
and rats (Oishi et al., 1992; Chikai et al., 1993). Concerning the re-
ceptor subtype involved in the anxiogenic-like effect of histamine,
it has been observed that the activation of H1 receptors appears to
have a prominent role (Malmberg-Aiello et al., 2002; Kumar et al.,
2007). This hypothesis is supported by the observation that mice
lacking histamine H1 receptors showed prolonged transfer latency
in the light/dark box test, indicating that mutant mice were less
fearful thanwild-type mice (Yanai et al., 1998). However, the role of
neuronal H4 receptors in the modulation of anxiety by the hista-
minergic system has not been elucidated. In the present study we
evaluated the effect of the activation of neuronal histamine H4
receptors in an anxiety-like condition, using the lightedark box
test. Surprisingly, the i.c.v. administration of the H4 receptor
agonist VUF 8430 produced a dose-dependent increase of the time
spent in the light compartment, indicating the induction of an
anxiolytic-like effect of intensity comparable to that exerted by
diazepam, used as reference drug. Pre-treatment with the H4 re-
ceptor antagonist JNJ 10191584 prevented this effect, further con-
firming the selective involvement of H4 receptor activation. In
contrast to anxiolytic reference drugs, VUF 8430 reduced the
number of transitions between the two compartments, a parameter
usually considered to evaluate the anxiolytic-like efficacy of com-
pounds along with the light/dark performance. However, the VUF
8430-induced inhibitory effect on transitions appeared at doses
lower than those effective as anxiolytic and it was JNJ 10191584
insensitive. These data suggest that this might be an unspecific
effect of VUF 8430, non-related to the activation of H4 receptors. A
similar profile of activity in the light dark box test was seen for the
H2 agonist impromidine. This compound increased the perma-
nence in the light compartment, but also decreased the number of
transitions (Malmberg-Aiello et al., 2002). Even if VUF 8430 has a
very low affinity for H2 receptors, we cannot exclude that the H4-
insensitive effect on transitions might be secondary to an activa-
tion of H2 receptors.
The light/dark box test is limited by its ability to yield false-
positive results if a drug increases general motor function.
Screening of locomotor activity appears to be necessary for elimi-
nating false-positive results. Administration of VUF 8430 did not
alter spontaneous mobility and exploratory activity in the hole
board test, excluding the presence of an altered locomotor activity
following H4 receptor activation that might lead to a misinterpre-
tation of the results obtained. It should be finally taken into account
that transitions in the lightedark box test have been reported to be
an index of exploration activity because of habituation over time,
and the time spent in each compartment to be a reflection of
aversion, but the measure with the highest validity seems to be the
percentage of time spent in each compartment (Bourin and
Hascoët, 2003).
To investigate to the role of the neuronal H4 receptors in the
modulation of memory processes, we evaluated the effects pro-
duced by VUF 8430 on a passive avoidance paradigm. The admin-
istration of the H4 agonist was able to prevent the memory
impairment induced by scopolamine, showing antiamnesic prop-
erties. In our experimental conditions, VUF 8430 did not induce any
procognitive effect. However, it should be taken into account that
an improvement in cognition of animals that have no memory
impairment is difficult to demonstrate in the passive avoidancetest. As a matter of fact, well known nootropic drugs such as pira-
cetam and aniracetam or cholinomimetics such as physostigmine
and oxotremorine, do not show any memory facilitation in unam-
nesic animals (Gouliaev and Senning, 1994).
It has been demonstrated that histamine is involved in learning
and memory. However, these studies have used many behavioral
tasks and obtained contradictory results. Nevertheless, the H3 re-
ceptor has been recently implicated in learning and memory pro-
cesses. Blockade of presynaptic H3 autoreceptors would enhance
the release of histamine and other transmitter systems involved in
cognitive processes and, indirectly, ameliorate cognitive perfor-
mances (Esbenshade et al., 2008). Present results suggest a bene-
ficial activity induced by neuronal H4 receptor stimulation on
memory impairments, extending and further clarifying the role of
the histaminergic system in the modulation of cognitive functions.
The modulation of eating behavior by activation of neuronal H4
receptors was evaluated in mice deprived of food for 12 h. These
experimental conditions were needed to highlight a reduction in
food intake. The i.c.v. administration of the H4 receptor agonist VUF
8430 significantly reduced food consumption, showing an ano-
rexant effect. This is the first evidence of a role of neuronal H4 re-
ceptors in the modulation of food intake. These results are in
agreement with the role of histamine in the regulation of appetite
and satiety (Masaki and Yoshimatsu, 2010). Brain histamine ap-
pears to suppress food intake via histamine H1 receptors. Centrally
administered histamine H1 receptor agonists suppressed food
consumption in rats (Lecklin et al., 1998), whereas injection of H1-
antagonists elicited food intake (Sakata et al., 1988; Ookuma et al.,
1993). However, relatively few studies have been carried out to
unequivocally establish a relationship between food consumption
and H1 receptors blockade in humans (Deng et al., 2010). Both H2-
agonists (Lecklin et al., 1998) and antagonists (Sakata et al., 1988)
centrally injected had no effect on food intake. More recently has
been postulated a role of H3 receptors in the eating behavior. H3
agonists increase feeding (Chiba et al., 2009) whereas H3 antago-
nists have been reported to induce weight loss (Malmlöf et al.,
2005). However, a stimulation of H3 autoreceptors would reduce
the histamine release increasing food consumption. The activation
of H3R in the anorexant mechanism of VUF 8430 appears very
unlikely.
Pharmacological or genetic loss of histamine or histamine re-
ceptor function in animals produces phenotypes that model human
depression (Haas et al., 2008). Endogenous histamine reduces the
time of immobility in the forced swimming test, suggesting an
antidepressant-like effect, via activation of H1 receptors (Lamberti
et al., 1998). More recently, the involvement of the H3 receptors has
been postulated since the H3 receptor antagonist and inhibitor of
the serotonin transporter JNJ 28583867 showed antidepressant-
like activity in animal models of depression (Barbier et al., 2007).
However, the activation of cerebral H4 receptors was devoid of any
effect on the mobility time in the mouse tail suspension test,
indicating the lack of any antidepressant-like effect by this hista-
mine receptor subtype.
VUF 8430 is also endowed with some affinity for the H3R sub-
type showing full agonist properties (Lim et al., 2009). However, it
has been supposed that H3R and H4R have distinct and contrasting
role in the mammalian brain. The H3R acts as autoreceptor on
histaminergic neuron endings. H3R activationmoderates histamine
release and synthesis and inhibits histaminergic neurotransmis-
sion. For this reason numerous H3 antagonists/inverse agonists
have been synthesized and studied in order to improve histamin-
ergic activity. On these bases, an involvement of H3R activation in
the pharmacological effects produced by VUF 8430 is very unlikely.
The histaminergic system is also involved in the regulation of lo-
comotor activity. Rotarod performance test was therefore
N. Galeotti et al. / Neuropharmacology 71 (2013) 141e147 147employed to demonstrate that the effects observed following the
administration of the H4 agonist VUF 8430 and the H4 antagonist
JNJ 10191584 in animal models were not due to impaired motor
function of these animals. Impaired motor coordination in animals
can affect the ability of animals to move their paws, and therefore,
may influence the paw withdraw latency during the pain efficacy
testing, the movements in the light/dark box during memory and
anxiety testing, the mobility time in the TST, the capability to reach
the food during feeding behavior determination. However, VUF
8430 and JNJ 10191584 did not produce any motor coordination
deficit of movement in rotarod performance assay. These results,
along with the lack of alteration of spontaneous mobility and
exploratory activity, indicate that the neuronal effects observed
following the administration of the H4 modulators are likely due to
specific antinociceptive, antiamnesic, anxiolytic and anorexant ef-
fects mediated by H4R agonism.
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